Cadrenal Therapeutics, Inc. Common Stock (CVKD) Earnings History
Annual and quarterly earnings data from 2022 to 2025
Loading earnings history...
CVKD EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CVKD Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
Download Data
Export CVKD earnings history in CSV or JSON format
Free sign-in required to download data
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Earnings Overview
As of May 8, 2026, Cadrenal Therapeutics, Inc. Common Stock (CVKD) reported trailing twelve-month net income of -$9M, reflecting +23.9% year-over-year growth. The company earned $-3.90 per diluted share over the past four quarters.
Looking at the long-term picture, CVKD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2022.
Cadrenal Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PTGX (-$115M net income, -282.8% margin), TCRX (-$124M net income, -1256.8% margin), NKTR (-$164M net income, -297.1% margin), CVKD has comparable earnings metrics. Compare CVKD vs PTGX →
CVKD Earnings vs Peers
Earnings metrics vs comparable public companies
CVKD Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$13M | -24.3% | -$13M | $-6.64 | - | - |
| 2024 | -$11M | -27.5% | -$11M | $-8.73 | - | - |
| 2023 | -$8M | -24.5% | -$8M | $-9.63 | - | - |
| 2022 | -$7M | - | -$3M | $-8.66 | - | - |
See CVKD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CVKD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CVKD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCVKD — Frequently Asked Questions
Quick answers to the most common questions about buying CVKD stock.
Is CVKD growing earnings?
CVKD EPS is $-3.90, with earnings growth accelerating to +23.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are CVKD's profit margins?
Cadrenal Therapeutics, Inc. Common Stock net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CVKD's earnings?
CVKD earnings data spans 2022-2025. The accelerating earnings trend is +23.9% YoY. Historical data enables comparison across business cycles.